jefferies 2017 global healthcare conference · • infectious disease ... ngs sample prep market...

1

Jefferies 2017 Global Healthcare ConferenceJune 2017

2

Some statements in this presentation may be forward-looking

statements, including, without limitation, statements regarding our

investment in high growth emerging markets and new products

and technologies, improvements to our operational efficiency and

our future financial performance. These statements are subject to

risks, uncertainties and other factors that could cause actual

results to differ materially from our expectations. Such factors

include, but are not limited to, recent changes to our global

organizational structure and executive management team,

difficulties in implementing our global ERP system, our ability to

develop and market new or improved products according to our

business plan, currency fluctuations and other factors discussed

in more detail in our recent filings with the SEC. We do not

undertake any obligation to publicly update any forward-looking

statements.

Forward-Looking Statements

3

• Continuous innovation

• Sales exceed $2 Billion

• Over 60 years of strong performance

• Apply key competencies to fuel growth

• More than 8,000 employees worldwide

• Complementary business mix

Bio-Rad Profile

A leading global provider of sophisticated products

to the life science research and diagnostic markets

4

• A leader in Life Science and Clinical Diagnostics

• Direct focus on the customer

• Invest in high growth emerging markets

• Improve operational efficiency and cash flow

Bio-Rad Strategy

Key Components

5

Leading Market Positions

Over 80% of sales are from products in which

Bio-Rad has a leading position in the market

DigitalBiology

Diagnostics• Autoimmune testing

• Diabetes Monitoring

• HIV testing

• Immuno-hematology

• Quality Controls

Life Science• Bio-chromatography

• DNA Amplification

• Electrophoresis

• Gel Image Analysis

• Protein Assays

6

Customer Focus

Biopharmaceutical

9%

Reference Labs

15%

Transfusion Labs

15%

Academic

23%

Industrial

3%Hospital Labs

35%

Diversified Customer Base

Recurring Revenues

Broad Product Base

Worldwide Presence

Americas

43%

Europe / Africa

38%Asia / Pacific

19%

7

Circle of Discovery -

Life Science Research Products

Gene Transfer and Modulation

Reagents expansion

Protein FunctionIdentification and interaction

ElectrophoresisOpportunities to gain market share

and leverage new technologies

Protein ExpressionMulti-analyte detection

Chromatography

Cellular AnalysisImaging and Cell Sorting

Food SafetyGrowth in food pathogen

testing

Digital BiologyDroplet Digital PCR

Image AnalysisGrowth markets in software and

digital microscopy

AmplificationPCR, qPCR

Gene Transfer and Modulation

Reagents expansion

Protein FunctionIdentification and interaction







ChromatographyChromatography




testing


testing




digital microscopy


digital microscopy



8

Clinical Diagnostics Products

Integrated Systems Approach

Quality Controls

Diagnostic Tests

Specialized

Testing

Instruments

• Quality controls

• Infectious disease

• AIDS/HIV

• Blood Virus detection

• Microbiology

• Diabetes monitoring

• Genetic disease screening

• Autoimmune testing

• Blood typing

9

Investing in High Growth Emerging Markets

Emerging Geographies

10

Investing in the Future

Technologies

ddPCR

GlobalizationSystems

New Markets

Cell Biology

Global Operating ModelGlobal ERP System

11

Investing in Cell Biology

Antibodies

Cell Visualization

Cell Counting

Flow Cytometry

Cell Sorter

12

Investing in Droplet Digital PCR

Droplet Digital System

Automated Droplet Generator

Reagents, Assays and

Consumables

13

Application of ddPCR

The Olivia Newton-John Cancer Research Institute

has become the first laboratory in Australia to be NATA

accredited for a breakthrough technology to perform

blood tests for melanoma patients to detect and analyse

cancer genes. This new approach is already saving lives.

Melanoma Liquid Biopsy

14

Building on a Key Franchise – RainDance Technologies

• Expands intellectual property portfolio

• Leverage technology to grow position in

NGS sample prep market

• Enables accelerated new product

development

RainDance Acquisition

RainDrop Plus

System

ThunderBolts Cancer and

Myeloid Panels

15

Illumina Bio-Rad Partnership

End-to-end single-cell sequencing solution

NextSeq™, BaseSpace™,

and SeqGeq™

SureCell™ WTA 3’

Library Prep KitsddSEQ™

Single-Cell Isolator

• Sensitive and unbiased characterization of transcriptional

signatures

• Scalable solution to accommodate a wide range of

experimental designs

16

Investing in the U.S. Immunohematology Market

We now have a complete portfolio of solutions

in the US with recent FDA approval

IH-1000

Tango infinity

Manual Reagents

Connectivity with IH-Com / IH-Web

Gel Card

Technology

IH-1000

17

Investing in our Future

Improve Operational Efficiency

Global ERP System

Operating Efficiency

Standardized Process

18

Investing in Globalization

Opportunities to Optimize Operations

Global Procurement

Global Manufacturing

Global Logistics

Shared Services

Global Commercial Organization

19

2017 Outlook

• Opportunity for Sales Growth

Good momentum for new products

Research funding holding steady

Expansion into U.S. Blood Typing market

Increased price pressure and competition for Diagnostics

• Significant Internal Investments

New product areas such as droplet digital PCR, cell biology, and

diagnostic sequencing

Global ERP and IT systems

Organization and operating model improvements

2017 Outlook

Organic Sales Growth ~ 4.0%

Gross Margin ~ 55.0%

Operating Margin ~ 7.0% Currency neutral

20

Driving Future Opportunity

• Top line growth

• Completing operating investments

• Driving efficiencies

• Expanding margins

Focus for 2017 - 2018

21

Thank you!

jefferies 2017 global healthcare conference · • infectious disease ... ngs sample prep market...

Documents